Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 10, 2018

Study Completion Date

February 10, 2018

Conditions
Prostate Cancer
Interventions
DRUG

docetaxel

3-weekly docetaxel therapy (starting dose of 75 mg/m2)

OTHER

Blood draws

Blood draws for determination of docetaxel plasma levels and exposure (AUC)

Trial Locations (20)

15009

UPMC CancerCenter - Beaver, Beaver

15102

UPMC CancerCenter - Upper St. Clair, Bethel Park

15122

UPMC CancerCenter - Jefferson, West Mifflin

15132

UPMC CancerCenter - Mckeesport, McKeesport

15146

UPMC CancerCenter - Monroeville, Monroeville

15215

UPMC CancerCenter - St. Margaret, Pittsburgh

15232

UPMC CancerCenter - Hillman Cancer Center, Pittsburgh

15237

UPMC CancerCenter - Passavant HOA, Pittsburgh

UPMC CancerCenter - Passavant OHA, Pittsburgh

15301

UPMC CancerCenter - Washington, Washington

15401

UPMC CancerCenter - Uniontown, Uniontown

15601

Arnold Palmer Cancer Center - Oakbrook, Greensburg

Arnold Palmer Cancer Center, Greensburg

15666

Arnold Palmer Medical Oncology - Mount Pleasant, Mount Pleasant

15701

UPMC CancerCenter - Indiana, Indiana

15901

UPMC CancerCenter at John P. Murtha Regional Cancer Center, Johnstown

16105

UPMC CancerCenter - New Castle, New Castle

16121

UPMC CancerCenter - Horizon, Farrell

16125

UPMC CancerCenter - Greenville, Greenville

16346

UPMC CancerCenter - Northwest, Seneca

All Listed Sponsors
collaborator

UPMC CancerCenter

UNKNOWN

lead

Saladax Biomedical, Inc.

INDUSTRY

NCT02376296 - Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | Biotech Hunter | Biotech Hunter